Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
Background: The multikinase inhibitor sunitinib has enhanced the treatment of renal cell carcinoma and gastrointestinal stromal tumor through an improved clinical response with decreased systemic toxicities. However, sunitinib is frequently associated with dermatological adverse reactions. The physi...
| Publicado en: | Supportive Care in Cancer Vol. 16; no. 6; pp. 557 - 567 |
|---|---|
| Autores principales: | , , , , , , , , , , , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
Jun2008
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105678149&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105678149 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09414355 O1J jtl: Supportive Care in Cancer issn: 09414355 maglogo: N pubinfo: dt: Jun2008 vid: 16 iid: 6 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 105678149 105678149 33045353 NLM18274784 2010022467 10.1007/s00520-008-0409-1 NLM18274784 105678149 ppf: 557 ppct: 10 formats: fmt: @attributes: type: P tig: atl: Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. aug: au: Rosenbaum SE Wu S Newman MA West DP Kuzel T Lacouture ME Rosenbaum, S E Wu, S Newman, M A West, D P Kuzel, T Lacouture, M E affil: Department of Dermatology, Northwestern University, Feinberg School of Medicine, 676 N. St. Clair St., Suite 1600, Chicago, IL 60611, USA sug: subj: Angiogenesis Inhibitors Adverse Effects Dermatitis Medicamentosa Etiology Heterocyclic Compounds Adverse Effects Indoles Adverse Effects Transferases Antagonists and Inhibitors Dermatitis Medicamentosa Epidemiology Dermatitis Medicamentosa Prevention and Control Incidence Quality of Life Human ab: Background: The multikinase inhibitor sunitinib has enhanced the treatment of renal cell carcinoma and gastrointestinal stromal tumor through an improved clinical response with decreased systemic toxicities. However, sunitinib is frequently associated with dermatological adverse reactions. The physical and psychosocial impact of frequent dermatological toxicities can affect consistent antineoplastic therapy and quality of life.Patients and Methods: Dermatological adverse reaction information was compiled from Pfizer Medical Information and from abstracts from the 2007 American Society of Clinical Oncology annual meeting, Prostate Cancer Symposium, and Gastrointestinal Cancers Symposium. Published clinical trials of sunitinib in MEDLINE, Cochrane Library, Cochrane Controlled Trials Register, and EMBASE Drugs and Pharmacology databases were also included. Information was accessed on or before June 30, 2007.Results: In the pooled analysis, all-grade hand-foot skin reaction occurred in 19% of patients (5% grades 3-4), skin discoloration in 28% (0% grades 3-4), dry skin in 16% (1% grades 3-4), skin rash in 13% (1% grades 3-4), dermatitis in 8% (2% grades 3-4), hair color changes in 10% (0% grades 3-4), alopecia in 6% (0% grades 3-4), and phototoxicity in <0.1%.Conclusions: Dermatological reactions associated with sunitinib occur frequently. Evidence-based treatment recommendations are needed in order to maximize quality of life and optimize clinical outcome. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|